If the rule goes into effect, the changes could make providing infusion services cost prohibitive for practices. The rule cuts reimbursement by using the lowest price drug manufacturers receive in one of 22 countries.
James Weber, MD, DHPA president and board chair, said, “Hundreds of thousands of patients are treated in DHPA member practices with medications that would be subject to this complicated scenario that bases reimbursements on what it costs to acquire the drugs in another country.”
DHPA is also concerned the rule threatens the viability of physician-owned medical practices. If the margins are too low for these practices to administer infusion services, patients could seek care in more expensive settings.
CMS skipped the normal notice-and-comment rulemaking process for the rule. The required comment period closes in late January. DHPA will take part in a nationwide demonstration opposing the rule Jan. 1.
More articles on specialty centers:
10 recent ASC leadership moves
Virginia ASC takes infection prevention to new level — 3 insights
Surgery Partners goes all-in on cardiology — 5 quotes on its quarterly performance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.